Ocular Short Term Debt from 2010 to 2025

OCUL Stock  USD 7.70  0.08  1.03%   
Ocular Therapeutix Short Term Debt yearly trend continues to be quite stable with very little volatility. The value of Short Term Debt is projected to decrease to about 1.7 M. From the period between 2010 and 2025, Ocular Therapeutix, Short Term Debt regression line of its data series had standard deviation of  4,000,101 and standard deviation of  4,000,101. View All Fundamentals
 
Short Term Debt  
First Reported
2013-12-31
Previous Quarter
3.3 M
Current Value
3.4 M
Quarterly Volatility
M
 
Yuan Drop
 
Covid
Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 13.7 M or Selling General Administrative of 41 M, as well as many indicators such as Price To Sales Ratio of 6.66, Dividend Yield of 0.0 or PTB Ratio of 3.69. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Latest Ocular Therapeutix's Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Ocular Therapeutix over the last few years. It is Ocular Therapeutix's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocular Therapeutix's overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Very volatile
   Short Term Debt   
       Timeline  

Ocular Short Term Debt Regression Statistics

Arithmetic Mean3,486,913
Geometric Mean2,418,789
Coefficient Of Variation114.72
Mean Deviation2,670,283
Median1,806,000
Standard Deviation4,000,101
Sample Variance16T
Range14.1M
R-Value(0.01)
Mean Square Error17.1T
R-Squared0.000063
Significance0.98
Slope(6,645)
Total Sum of Squares240T

Ocular Short Term Debt History

20251.7 M
20241.8 M
20231.6 M
20223.2 M
20213.2 M
202011 M

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as Short Term Debt, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short Term Debt1.8 M1.7 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.29)
Revenue Per Share
0.529
Quarterly Revenue Growth
0.083
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.